<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02515422</url>
  </required_header>
  <id_info>
    <org_study_id>2014/99</org_study_id>
    <nct_id>NCT02515422</nct_id>
  </id_info>
  <brief_title>Subcutaneous Wound Infiltration of Ketamine or Bupivacaine Pain Perception After Cesarean Section</brief_title>
  <official_title>Subcutaneous Wound Infiltration of Ketamine is Superior to Bupivacaine in Terms of Pain Perception and Opioid Consumption After Cesarean Section: a Double-blinded Randomized Placebo Controlled Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huseyin Aksoy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kayseri Education and Research Hospital</source>
  <brief_summary>
    <textblock>
      Aim: To assess the analgesic efficacy of subcutaneous infiltration of ketamine, either alone&#xD;
      or as an adjuvant to bupivacaine, following CS and to compare their effects on postoperative&#xD;
      pain scores and opioid consumption.&#xD;
&#xD;
      Methods: Included patients were allocated to four treatment groups using computer-generated&#xD;
      randomization number chart as follows; Group 1 (Ketamine, n=30) received subcutaneous&#xD;
      infiltration of ketamine, Group 2 (Bupivacaine, n=30) received subcutaneous infiltration of&#xD;
      bupivacaine 0.5%, Group 3 (Ketamine+Bupivacaine, n=30) received subcutaneous infiltration of&#xD;
      ketamine+bupivacaine 0.5% and Group 4 (Placebo, n=30) received subcutaneous infiltration of&#xD;
      placebo (0.9% saline solution). Patients, anesthetist, surgeon, and other medical and nursing&#xD;
      staff were blinded to the contents of the medications. VAS scores at resting and on coughing&#xD;
      and analgesic consumptions were compared.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      the Group 1 (Ketamine, n=30) received subcutaneous infiltration of ketamine 1 mg/kg&#xD;
      (Ketalar®, 10 mL inj., 50 mg ketamine hydrochloride/ml, Pfizer Drug Company, USA). The Group&#xD;
      2 (Bupivacaine, n=30) received subcutaneous infiltration of 20 mL (100 mg) of bupivacaine&#xD;
      0.5% (Marcaine®, 20 mL inj. 5 mg bupivacaine hydrochloride/ml, AstraZeneca Drug Company,&#xD;
      Turkey). The Group 3 (Ketamine+Bupivacaine, n=30) received subcutaneous infiltration of&#xD;
      ketamine 1 mg/kg (Ketalar®) plus subcutaneous infiltration of 20 mL (100 mg) of bupivacaine&#xD;
      0.5% (Marcaine®). The Group 4 (Placebo, n=30) received subcutaneous infiltration of 30 mL&#xD;
      placebo (0.9% saline solution). All medications were diluted with sterile 0.9% saline&#xD;
      solution to 30 ml solutions in the similar volume and shape syringes and were infiltrated&#xD;
      subcutaneously along the skin wound edges and close to the fascia prior to skin closure.&#xD;
      There were four separate syringes which were prepared by an anesthesiology technician for&#xD;
      four different treatment groups labeled G1, G2, G3 and G4 containing the ketamine,&#xD;
      bupivacaine, ketamine plus bupivacaine and normal saline solution. Patients, anesthetist,&#xD;
      surgeon, and other medical and nursing staff were blinded to the contents of the medications.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative visual analog scale pain score</measure>
    <time_frame>Postoperative 12 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative opioid consumption</measure>
    <time_frame>Postoperative 12 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>Group 1, Ketamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ketamine, 1 mg/kg (Ketalar®, 10 mL inj., 50 mg ketamine hydrochloride/ml, Pfizer Drug Company, USA) was administered subcutaneously before the closure of pfannenstiel incision.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2, Bupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bupivacaine 0.5% 20 mL (100 mg) (Marcaine®, 20 mL inj. 5 mg bupivacaine hydrochloride/ml, AstraZeneca Drug Company, Turkey) was administered subcutaneously before the closure of pfannenstiel incision.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3, Ketamine+Bupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ketamine 1 mg/kg (Ketalar®) and bupivacaine 0.5% (100 mg) (Marcaine®) were administered subcutaneously before the closure of pfannenstiel incision.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4, Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (0.9% saline solution) was administered subcutaneously before the closure of pfannenstiel incision.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Subcutaneous infiltration of ketamine</description>
    <arm_group_label>Group 1, Ketamine</arm_group_label>
    <arm_group_label>Group 3, Ketamine+Bupivacaine</arm_group_label>
    <other_name>Ketalar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>Subcutaneous infiltration of bupivacaine</description>
    <arm_group_label>Group 2, Bupivacaine</arm_group_label>
    <arm_group_label>Group 3, Ketamine+Bupivacaine</arm_group_label>
    <other_name>Marcaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (0.9% saline solution)</intervention_name>
    <arm_group_label>Group 4, Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  singleton term pregnancy,&#xD;
&#xD;
          -  between 38-41th weeks of gestation,&#xD;
&#xD;
          -  absence of any medical or obstetrical problems.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  multiple pregnancies,&#xD;
&#xD;
          -  intrauterine fetal deaths,&#xD;
&#xD;
          -  active stage of labor,&#xD;
&#xD;
          -  obstetric emergencies such as antepartum hemorrhage, eclampsia and acute fetal&#xD;
             distress,&#xD;
&#xD;
          -  special request for general anesthesia,&#xD;
&#xD;
          -  history of allergic reaction or sensitivity to any of the drugs used in the study,&#xD;
&#xD;
          -  reflected anxiety and depression during the cesarean operation,&#xD;
&#xD;
          -  any systemic diseases (chronic hypertension, thyroid diseases, renal or hepatic&#xD;
             insufficiency, psychiatric disorders,&#xD;
&#xD;
          -  chronic pain syndrome, epilepsy or intracranial hypertension)&#xD;
&#xD;
          -  medications that would affect the perception of pain,&#xD;
&#xD;
          -  current or past history of narcotic use or a history of narcotic abuse,&#xD;
&#xD;
          -  inability to understand how to score a 10-cm visual analogue scale (VAS) for pain.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kayseri Educational and Research Hospital</name>
      <address>
        <city>Kayseri</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <study_first_submitted>July 29, 2015</study_first_submitted>
  <study_first_submitted_qc>August 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2015</study_first_posted>
  <last_update_submitted>August 3, 2015</last_update_submitted>
  <last_update_submitted_qc>August 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Kayseri Education and Research Hospital</investigator_affiliation>
    <investigator_full_name>Huseyin Aksoy</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>Caesarean Section</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

